OBJECTIVES The aim of this study was to assess the safety and effectiveness of the COBRA Polyzene-F NanoCoated Coronary Stent System (CeloNova Biosciences, San Antonio, Texas) for the treatment of de novo coronary artery lesions.
Cutlip et al. Clinical events to 270 days are shown in Table 3 . Figure 2B . In-stent binary angiographic restenosis occurred in 25.6% of patients, including 6 patients (5%) with follow-up diameter stenosis >70% and 1 patient with late total occlusion.
PRE-SPECIFIED SUBGROUP ANALYSES. Nine-month clinical and angiographic outcomes were assessed in 4 pre-specified subgroups (Online Tables 1 and 2 ). Values are n (%) or mean AE SD. In the present study, the frequency of clinically driven TLR was low, and the safety hazards associ- The absence of stent thrombosis in our study also supports findings from preclinical work that showed markedly reduced platelet adherence and thrombogenicity for stents with a nanolayer of PzF (10, 21 Values are mean AE SD or n (%). Cutlip et al.
